Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Porto – page 22

498 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Porto at a glance
498
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

498 trials in Porto

Open in trial search

Schizophrenia

Not recruiting

Relative Bioavailability of LY03010 versus Paliperidone Palmitate (with Risperidone background) in Healthy Volunteers for Schizophrenia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Risperidone
  • Sponsor:Geneora Pharma (Shijiazhuang) Co. Ltd.

Aplastic anaemia+1

Not recruiting

A study to compare the absorption of eltrombopag olamine in healthy volunteers to ensure the tablets work the same way for patients with thrombocytopenia or aplastic anemia.

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Hypogonadism male

Not recruiting

A study to compare the absorption of testosterone transdermal gel in healthy female subjects

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Testosterone
  • Sponsor:Laboratorios Leon Farma S.A.

A study comparing how midazolam oromucosal solution and midazolam solution for injection are absorbed in healthy volunteers

Not recruiting
Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Midazolam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Nicotine dependence

Not recruiting

A study to evaluate how cytisinicline works in patients with nicotine addiction and kidney problems or those undergoing dialysis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Cytisinicline
  • Sponsor:Achieve Life Sciences Inc.

Angelman's syndrome

Not recruiting

A Study Testing the Safety and How Well GTX-102 Works in Adults and Children with Angelman Syndrome

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Apazunersen
  • Sponsor:Ultragenyx Pharmaceutical Inc.

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Aplastic anaemia+1

Not recruiting

A Study Comparing Eltrombopag Tablets in Healthy Volunteers to Test if Two Forms of the Medicine Work the Same Way in the Body After Taking with Food

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Endometrial cancer+2

Not recruiting

A study comparing how lenvatinib capsules are absorbed in the body in healthy volunteers under fasting and fed conditions

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Lenvatinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Neovascular age-related macular degeneration

Not recruiting

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Chronic kidney disease

Not recruiting

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Empagliflozin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

  • Vision disorders
  • Genetic disorders
  • Treatment efficacy studies
02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

  • Blood cancers
  • Solid tumors
  • Immunotherapy
03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

  • Inflammatory skin conditions
  • Autoimmune disorders
  • Novel biologics
04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

  • Heart conditions
  • Metabolic diseases
  • Weight management
05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

  • Neurological disorders
  • Rare diseases
  • Pain management
Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.